Adbry Dosage
Generic name: TRALOKINUMAB 150mg in 1mL
Dosage form: injection, solution
Drug class: Interleukin inhibitors
Medically reviewed by Drugs.com. Last updated on May 24, 2024.
Vaccination Prior to Treatment
Complete all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with ADBRY.
Important Administration Instructions
- ADBRY is administered by subcutaneous injection.
- ADBRY is intended for use under the guidance of a healthcare provider. Provide proper training to patients and/or caregivers on the preparation and administration of ADBRY prior to use according to the "Instructions for Use".
Use of the Autoinjector
- The ADBRY autoinjector is for use in adults only.
- A caregiver or adult patient may inject ADBRY using the autoinjector.
Use of the Prefilled Syringe
- The ADBRY prefilled syringe is for use in adults and pediatric patients 12 years of age and older.
- A caregiver or patient 12 years of age and older may inject ADBRY using the prefilled syringe. In pediatric patients 12 years of age and older, administer ADBRY under the supervision of an adult.
Administration Instructions
- Administer subcutaneous injection into the thigh or abdomen, except for the 2 inches (5 cm) around the navel. The upper arm can also be used if a caregiver administers the injection.
- DO NOT inject ADBRY into skin that is tender, damaged, bruised, or scarred.
- For adults taking the initial loading dose of 600 mg, administer each of the injections (four ADBRY 150 mg injections using prefilled syringes or two ADBRY 300 mg injections using autoinjectors) at different injection sites within the same body area.
- For the subsequent 300 mg doses using the prefilled syringe, administer the two ADBRY 150 mg injections at different injection sites within the same body area, rotating the body area with each subsequent set of injections.
- For the subsequent 300 mg doses using the autoinjector, administer one ADBRY 300 mg injection, rotating the body area with each subsequent injection
- For pediatric patients 12 years of age and older taking the initial loading dose of 300 mg, use prefilled syringes to administer the two ADBRY 150 mg injections at different injection sites within the same body area.
- For the subsequent 150 mg doses, use a prefilled syringe to administer one ADBRY 150 mg injection, rotating the body area with each subsequent injection.
- The ADBRY "Instructions for Use" contains more detailed instructions on the preparation and administration of ADBRY.
Recommended Dosage
Dosage in Adults
The recommended dosage for adults is:
| Initial Loading Dose | Subsequent Dosage | |
|---|---|---|
| Prefilled syringe | 600 mg (four 150 mg injections) | 300 mg (two 150 mg injections) every other week |
| Autoinjector | 600 mg (two 300 mg injections) | 300 mg (one 300 mg injection) every other week |
After 16 weeks of treatment, for adult patients with body weight below 100 kg who achieve clear or almost clear skin, a dosage of 300 mg every 4 weeks may be considered.
Concomitant Topical Therapies
ADBRY can be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used, but should be reserved for problem areas only, such as the face, neck, intertriginous and genital areas.
Missed Doses
If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.
Preparation for Use
- Before injection, remove ADBRY prefilled syringes or autoinjectors from the refrigerator and allow to reach room temperature (at least 30 minutes for the prefilled syringes and at least 45 minutes for the autoinjectors) without removing the needle cover or cap, respectively.
- After removal from the refrigerator, ADBRY may be kept at room temperature up to 30°C (86°F) and must be used within 14 days or discarded.
- Inspect ADBRY visually for particulate matter and discoloration prior to administration. ADBRY injection is a clear to opalescent, colorless to pale yellow solution. Do not use if the liquid contains visible particulate matter, is discolored or cloudy (other than clear to opalescent, colorless to pale yellow).
- ADBRY does not contain preservatives; therefore, discard any unused product.
Frequently asked questions
More about Adbry (tralokinumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (7)
- Drug images
- Side effects
- During pregnancy
- FDA approval history
- Drug class: interleukin inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
See also:
Opzelura
Opzelura (ruxolitinib) cream is used for the treatment of atopic dermatitis and vitiligo. Includes ...
Eucrisa
Eucrisa (crisaborole) is used to treat mild to moderate eczema (atopic dermatitis) Includes Eucrisa ...
Cibinqo
Cibinqo (abrocitinib) tablets are used for the treatment of moderate to severe eczema (atopic ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Temovate
Temovate is used for atopic dermatitis, dermatitis, dermatological disorders, eczema, lichen ...
Lidex
Lidex is used for atopic dermatitis, dermatitis, eczema, psoriasis
Clobex
Clobex is used for atopic dermatitis, dermatitis, dermatological disorders, eczema, lichen planus ...
Olux
Olux is used for atopic dermatitis, dermatitis, dermatological disorders, eczema, lichen planus ...
Clodan
Clodan is used for atopic dermatitis, dermatitis, dermatological disorders, eczema, lichen planus ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
